APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Growth and Trends Forecast to 2032

31 December 2025112 pages

Choose your research edition.

Industry ResearchGranulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

According to APO Research, the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market include Teva, Novartis, Merck, Pfizer, Amgen, SL Pharm, North China Pharmaceutical, Kyowa Kirin and Intas, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Company

Teva

Novartis

Merck

Pfizer

Amgen

SL Pharm

North China Pharmaceutical

Kyowa Kirin

Intas

Hayao Group

GenSci

Dr. Reddy

Dong-A Socio

Chugai Pharmaceutical

Amoytop

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Type

Filgrastim

Lipefigrastim

Pefigrastim

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Application

Oncology

Blood Disease

Other

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2021-2026) Table 4. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2027-2032) Table 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Type (2021-2026) Table 9. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Application (2021-2026) Table 24. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends Table 37. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers Table 38. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges Table 39. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints Table 40. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Company Headquarters & Area Served Table 44. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company, Product Type & Application Table 45. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Teva Company Information Table 49. Teva Business Overview Table 50. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 52. Teva Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 57. Novartis Recent Development Table 58. Merck Company Information Table 59. Merck Business Overview Table 60. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 62. Merck Recent Development Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 67. Pfizer Recent Development Table 68. Amgen Company Information Table 69. Amgen Business Overview Table 70. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 72. Amgen Recent Development Table 73. SL Pharm Company Information Table 74. SL Pharm Business Overview Table 75. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 77. SL Pharm Recent Development Table 78. North China Pharmaceutical Company Information Table 79. North China Pharmaceutical Business Overview Table 80. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 82. North China Pharmaceutical Recent Development Table 83. Kyowa Kirin Company Information Table 84. Kyowa Kirin Business Overview Table 85. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 87. Kyowa Kirin Recent Development Table 88. Intas Company Information Table 89. Intas Business Overview Table 90. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 92. Intas Recent Development Table 93. Hayao Group Company Information Table 94. Hayao Group Business Overview Table 95. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 97. Hayao Group Recent Development Table 98. GenSci Company Information Table 99. GenSci Business Overview Table 100. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 102. GenSci Recent Development Table 103. Dr. Reddy Company Information Table 104. Dr. Reddy Business Overview Table 105. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 107. Dr. Reddy Recent Development Table 108. Dong-A Socio Company Information Table 109. Dong-A Socio Business Overview Table 110. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 112. Dong-A Socio Recent Development Table 113. Chugai Pharmaceutical Company Information Table 114. Chugai Pharmaceutical Business Overview Table 115. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 117. Chugai Pharmaceutical Recent Development Table 118. Amoytop Company Information Table 119. Amoytop Business Overview Table 120. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 122. Amoytop Recent Development Table 123. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 125. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2026) Table 126. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share Forecast by Country (2027-2032) Table 128. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 130. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2026) Table 131. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 135. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2026) Table 136. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share Forecast by Country (2027-2032) Table 138. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 140. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2026) Table 141. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share Forecast by Country (2027-2032) Table 143. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2026) Table 146. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share Forecast by Country (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Image Figure 3. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2021-2032) Figure 7. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Filgrastim Image Figure 13. Global Filgrastim Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Lipefigrastim Image Figure 15. Global Lipefigrastim Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Pefigrastim Image Figure 17. Global Pefigrastim Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type 2025 VS 2032 Figure 20. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Type (2021-2032) Figure 21. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Type (2021-2032) Figure 23. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Type (2021-2032) Figure 25. Oncology Image Figure 26. Global Oncology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Blood Disease Image Figure 28. Global Blood Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Other Image Figure 30. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Application (2021-2032) Figure 34. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Application (2021-2032) Figure 36. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 43. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 46. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 49. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 52. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • Lipefigrastim
  • Pefigrastim
Applications
  • Oncology
  • Blood Disease
  • Other
Companies covered
  • Teva
  • Novartis
  • Merck
  • Pfizer
  • Amgen
  • SL Pharm
  • North China Pharmaceutical
  • Kyowa Kirin
  • Intas
  • Hayao Group
  • GenSci
  • Dr. Reddy
  • Dong-A Socio
  • Chugai Pharmaceutical
  • Amoytop

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
  8. 1.5.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (2021-2032)
2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Filgrastim
  3. 2.1.2 Lipefigrastim
  4. 2.1.3 Pefigrastim
  5. 2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
  6. 2.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Regions
  10. 2.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Type (2021-2026)
3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Oncology
  3. 3.1.2 Blood Disease
  4. 3.1.3 Other
  5. 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
  6. 3.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Regions
  10. 3.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends
  2. 4.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers
  3. 4.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges
  4. 4.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (2021-2026)
  2. 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company, Product Type & Application
  5. 5.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Teva
  2. 6.1.1 Teva Company Information
  3. 6.1.2 Teva Business Overview
  4. 6.1.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  6. 6.1.5 Teva Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Pfizer
  20. 6.4.1 Pfizer Company Information
  21. 6.4.2 Pfizer Business Overview
  22. 6.4.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  24. 6.4.5 Pfizer Recent Developments
  25. 6.5 Amgen
  26. 6.5.1 Amgen Company Information
  27. 6.5.2 Amgen Business Overview
  28. 6.5.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  30. 6.5.5 Amgen Recent Developments
  31. 6.6 SL Pharm
  32. 6.6.1 SL Pharm Company Information
  33. 6.6.2 SL Pharm Business Overview
  34. 6.6.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  36. 6.6.5 SL Pharm Recent Developments
  37. 6.7 North China Pharmaceutical
  38. 6.7.1 North China Pharmaceutical Company Information
  39. 6.7.2 North China Pharmaceutical Business Overview
  40. 6.7.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  42. 6.7.5 North China Pharmaceutical Recent Developments
  43. 6.8 Kyowa Kirin
  44. 6.8.1 Kyowa Kirin Company Information
  45. 6.8.2 Kyowa Kirin Business Overview
  46. 6.8.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  48. 6.8.5 Kyowa Kirin Recent Developments
  49. 6.9 Intas
  50. 6.9.1 Intas Company Information
  51. 6.9.2 Intas Business Overview
  52. 6.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  54. 6.9.5 Intas Recent Developments
  55. 6.10 Hayao Group
  56. 6.10.1 Hayao Group Company Information
  57. 6.10.2 Hayao Group Business Overview
  58. 6.10.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  60. 6.10.5 Hayao Group Recent Developments
  61. 6.11 GenSci
  62. 6.11.1 GenSci Company Information
  63. 6.11.2 GenSci Business Overview
  64. 6.11.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  66. 6.11.5 GenSci Recent Developments
  67. 6.12 Dr. Reddy
  68. 6.12.1 Dr. Reddy Company Information
  69. 6.12.2 Dr. Reddy Business Overview
  70. 6.12.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  72. 6.12.5 Dr. Reddy Recent Developments
  73. 6.13 Dong-A Socio
  74. 6.13.1 Dong-A Socio Company Information
  75. 6.13.2 Dong-A Socio Business Overview
  76. 6.13.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  78. 6.13.5 Dong-A Socio Recent Developments
  79. 6.14 Chugai Pharmaceutical
  80. 6.14.1 Chugai Pharmaceutical Company Information
  81. 6.14.2 Chugai Pharmaceutical Business Overview
  82. 6.14.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  84. 6.14.5 Chugai Pharmaceutical Recent Developments
  85. 6.15 Amoytop
  86. 6.15.1 Amoytop Company Information
  87. 6.15.2 Amoytop Business Overview
  88. 6.15.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  90. 6.15.5 Amoytop Recent Developments
7 North America
  1. 7.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst